FDA Accepts Supplemental BLA for TALVEY (TALQUETAMAB-TGVS) by Janssen
The FDA has accepted a supplemental Biologics License Application (BLA) for TALVEY, an investigational T-cell engager.
Therapeutic Area
Therapeutic area intelligence for T-cell engagers with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.